RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives $5.29 Average PT from Analysts

RAPT Therapeutics, Inc. (NASDAQ:RAPT) has earned an average recommendation of “Hold” from the nine analysts that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $5.29.

Separately, HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th.

RAPT Therapeutics Price Performance

NASDAQ:RAPT opened at $1.31 on Thursday. RAPT Therapeutics has a 1-year low of $0.79 and a 1-year high of $9.65. The firm’s fifty day moving average price is $1.17 and its 200 day moving average price is $1.48. The firm has a market cap of $172.93 million, a price-to-earnings ratio of -0.47 and a beta of -0.31.

RAPT Therapeutics (NASDAQ:RAPT) last posted its earnings results on Thursday, March 6th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.69). As a group, analysts expect that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds have recently modified their holdings of RAPT. Picton Mahoney Asset Management boosted its position in shares of RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after acquiring an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. Readystate Asset Management LP bought a new position in shares of RAPT Therapeutics in the third quarter valued at about $36,000. Barclays PLC raised its stake in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after acquiring an additional 29,195 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in RAPT Therapeutics in the 4th quarter worth approximately $63,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.